Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 16/20 | 0.66 |
| ▸ | PAK4 | O96013 | 3/20 | 0.61 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.61 |
| ▸ | JAK2 | O60674 | 1/20 | 0.61 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.61 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
| ▸ | FYN | P06241 | 1/20 | 0.61 |
| ▸ | CSF1R | P07333 | 1/20 | 0.61 |
| ▸ | RET | P07949 | 1/20 | 0.61 |
| ▸ | IGF1R | P08069 | 1/20 | 0.61 |
| ▸ | MET | P08581 | 1/20 | 0.61 |
| ▸ | ROS1 | P08922 | 1/20 | 0.61 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.61 |
| ▸ | PRKACA | P17612 | 1/20 | 0.61 |
| ▸ | FLT1 | P17948 | 1/20 | 0.61 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.61 |
| ▸ | KDR | P35968 | 1/20 | 0.61 |
| ▸ | SYK | P43405 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4077954 | 0.93 | PAK4 (0.59) | NTRK1PAK4DYRK3JAK2PRKD3 | |
| SCHEMBL4066282 | 0.91 | IGF1R (0.71) | NTRK1PAK4DYRK3JAK2PRKD3 | |
| SCHEMBL23217099 | 0.86 | NTRK1 (0.70) | NTRK1 | |
| SCHEMBL29794656 | 0.86 | NTRK1 (0.70) | NTRK1 | |
| SCHEMBL3338355 | 0.86 | NTRK1 (0.70) | NTRK1 | |
| SCHEMBL4156755 | 0.84 | NTRK1 (0.76) | NTRK1JAK2 | |
| SCHEMBL4076751 | 0.83 | NTRK1 (0.66) | NTRK1 | |
| SCHEMBL3343506 | 0.82 | NTRK1 (0.84) | NTRK1JAK2 | |
| SCHEMBL30010012 | 0.82 | NTRK1 (0.84) | NTRK1JAK2 | |
| SCHEMBL23216995 | 0.82 | NTRK1 (0.84) | NTRK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005396-A1 | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005396-A1 | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain | P2RX3, DPYD, TYMP | NTRK1 3656/4885PAK4 1337/4885DYRK3 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.